| 000 | 01040 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250515145137.0 | ||
| 264 | 0 | _c20081110 | |
| 008 | 200811s 0 0 eng d | ||
| 022 | _a1538-3598 | ||
| 024 | 7 |
_a10.1001/jama.2008.510 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGoodarzi, Mark O | |
| 245 | 0 | 0 |
_aGlucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point? _h[electronic resource] |
| 260 |
_bJAMA _cNov 2008 |
||
| 300 |
_a2051-3 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 |
_aCardiovascular Diseases _xetiology |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xcomplications |
| 650 | 0 | 4 |
_aDiabetic Angiopathies _xetiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aInsulin Resistance |
| 700 | 1 | _aPsaty, Bruce M | |
| 773 | 0 |
_tJAMA _gvol. 300 _gno. 17 _gp. 2051-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1001/jama.2008.510 _zAvailable from publisher's website |
| 999 |
_c18446159 _d18446159 |
||